Clinical trial · Interventional
Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma
NCT00327314CI-TRIAL-00000543unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The protocol aims at reducing transplant toxicity and mortality in patients with multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hematopoietic cell transplantation | Procedure | — | UNRESOLVED |
| Transplantation | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of Durie-Salmon stage IIA-IIIB multiple myeloma * Age \> 18 and ≤ 65 years at the start of the donor search * Presence of concurrent co-morbidities precluding myeloablative conditioning or refusal to undergo a conventional allogeneic transplant * Capacity to give informed consent Exclusion Criteria: * Age \> 65 years * Karnofsky performance status score \< 60% * Progressive disease or stable disease for less than three months * Central nervous system involvement * Left ventricular ejection fraction \< 35% or symptomatic heart failure * Poorly controlled hypertension * Pulmonary dysfunction with diffusing capacity for carbon monoxide (DLCO) \< 40% and/or need for continuous oxygen supplementation * Abnormal liver disease with a serum bilirubin greater than twice normal or SGOT and/or SGPT greater than four times the upper limits of normal * HIV positive patients * Pregnancy * Refusal to use contraceptive techniques during and for 12 months following treatment
References
Publications (0)
Data not yet available
No reference posted for this study.